Literature DB >> 25082628

Teleneurology in stroke management: costs of service in different organizational models.

René Handschu1, Mateusz Scibor, Martin Nückel, Dirk Asshoff, Barbara Willaczek, Frank Erbguth, Stefan Schwab, Frank Daumann.   

Abstract

Telemedicine is in increasing use in clinical neuroscience such as acute stroke care, especially by applying remote audiovisual communication for patient evaluation. However, telephone consultation was also used linking stroke centres to smaller hospitals. We compared costs of telestroke services using audiovisual and telephone communication in different organizational models. Within a small network in Northern Bavaria video-based teleconsultation (VTC) and telephone advice (TA) was provided for evaluation of acute stroke patients on a weekly rotation. The costs of the admissions process with or without one of both methods of telemedicine were calculated and compared from the perspective of the spoke hospital. Different levels of service and network size were modelled and costs of transfers as well as loss of revenues were calculated. Yearly total labour costs were 415,000 € for an on-site service VTC-service compared to 61,000 € in an on-call service. Additional costs for one teleconsultation were 109.55 € in VTC and 49.82 € in TA (VTC/TA ratio 2.2). The ratio decreased to 0.8 when accounting for costs of transfer and loss of reimbursement for all patients transferred as transfer of patients to the stroke centre was more frequent after TA (9.1 vs. 14.9%full-time on-site ser). Costs of one QALY gained by using VTC instead of TA ranged from 115.00 € to 515.86 € depending on the different models. In the first view TA looks like the less expensive method as it is easy to access and works without additional costs. When accounting for all disadvantages TA becomes slightly more expensive. In telestroke care VTC should be recommended as the method of choice also from an economic perspective.

Entities:  

Mesh:

Year:  2014        PMID: 25082628     DOI: 10.1007/s00415-014-7450-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  [Updates by the Stroke Society].

Authors:  Heinrich Audebert; Otto Busse
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

2.  Is mobile teleconsulting equivalent to hospital-based telestroke services?

Authors:  Heinrich J Audebert; Sandra Boy; Ralf Jankovits; Philipp Pilz; Jochen Klucken; Nando P Fehm; Johannes Schenkel
Journal:  Stroke       Date:  2008-09-11       Impact factor: 7.914

3.  Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe.

Authors:  Muhammad A Pervez; Gisele Silva; Shihab Masrur; Rebecca A Betensky; Karen L Furie; Renzo Hidalgo; Fabricio Lima; Eric S Rosenthal; Natalia Rost; Anand Viswanathan; Lee H Schwamm
Journal:  Stroke       Date:  2009-11-12       Impact factor: 7.914

4.  The cost-effectiveness of telestroke in the treatment of acute ischemic stroke.

Authors:  R E Nelson; G M Saltzman; E J Skalabrin; B M Demaerschalk; J J Majersik
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

5.  Observational study of telephone consults by stroke experts supporting community tissue plasminogen activator delivery.

Authors:  Jennifer J Majersik; William J Meurer; Shirley A Frederiksen; Amaria M Sandretto; Zhenzhen Xu; Edward B Goldman; Phillip A Scott
Journal:  Acad Emerg Med       Date:  2012-09       Impact factor: 3.451

6.  Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria.

Authors:  Heinrich J Audebert; Christian Kukla; Stephan Clarmann von Claranau; Johannes Kühn; Bijan Vatankhah; Johannes Schenkel; Guntram W Ickenstein; Roman L Haberl; Markus Horn
Journal:  Stroke       Date:  2004-12-29       Impact factor: 7.914

7.  Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives.

Authors:  Jeffrey A Switzer; Bart M Demaerschalk; Jipan Xie; Liangyi Fan; Kathleen F Villa; Eric Q Wu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-12-04

8.  National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness.

Authors:  Lars Ehlers; Wilhelmina Maria Müskens; Lotte Groth Jensen; Mette Kjølby; Grethe Andersen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Telemedicine in emergency evaluation of acute stroke: interrater agreement in remote video examination with a novel multimedia system.

Authors:  René Handschu; Rebekka Littmann; Udo Reulbach; Charly Gaul; Josef G Heckmann; Bernhard Neundörfer; Mateusz Scibor
Journal:  Stroke       Date:  2003-11-13       Impact factor: 7.914

10.  Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study.

Authors:  Ramon Luengo-Fernandez; Alastair M Gray; Linda Bull; Sarah Welch; Fiona Cuthbertson; Peter M Rothwell
Journal:  Neurology       Date:  2013-10-09       Impact factor: 9.910

View more
  3 in total

1.  Use of a telestroke service for evaluation of non-stroke neurological cases.

Authors:  René Handschu; Angela Wacker; Mateusz Scibor; Camelia Sancu; Stefan Schwab; Frank Erbguth; Patrick Oschmann; David Stark; Lars Marquardt
Journal:  J Neurol       Date:  2015-03-21       Impact factor: 4.849

2.  New hospital structure in the twenty-first century: the position of level III (tertiary) neurological and stroke care in a changing healthcare system.

Authors:  Tamás Szentes; László Kovács; Csaba Óváry
Journal:  Springerplus       Date:  2016-11-29

3.  Implementation and Evaluation of an Economic Model for Telestroke: Experience from Virtuall, France.

Authors:  Nolwenn Riou-Comte; Gioia Mione; Lisa Humbertjean; Arielle Brunner; Arnaud Vezain; Karine Lavandier; Sophie Marchal; Serge Bracard; Marc Debouverie; Sébastien Richard
Journal:  Front Neurol       Date:  2017-11-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.